

# Pia Bernasconi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7597369/publications.pdf>

Version: 2024-02-01

88  
papers

3,082  
citations

136885

32  
h-index

175177

52  
g-index

90  
all docs

90  
docs citations

90  
times ranked

3985  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. <i>Journal of Neuroimmunology</i> , 2002, 131, 179-185.	1.1	151
2	Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 413-423.	1.8	135
3	Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. <i>Journal of the Neurological Sciences</i> , 2003, 212, 31-36.	0.3	126
4	Transforming growth factor- $\beta$ 1 and fibrosis in congenital muscular dystrophies. <i>Neuromuscular Disorders</i> , 1999, 9, 28-33.	0.3	122
5	Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy. <i>Journal of Neuroimmunology</i> , 2006, 175, 77-86.	1.1	114
6	Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. <i>Annals of Neurology</i> , 2010, 67, 726-738.	2.8	103
7	Decorin and biglycan expression is differentially altered in several muscular dystrophies. <i>Brain</i> , 2005, 128, 2546-2555.	3.7	87
8	Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection-related epilepsy syndrome. <i>Epilepsia Open</i> , 2019, 4, 344-350.	1.3	85
9	Increased Expression of $\beta$ -Chemokines in Muscle of Patients with Inflammatory Myopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 164-169.	0.9	81
10	Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: A longitudinal MRI study. <i>Experimental Neurology</i> , 2011, 231, 30-37.	2.0	81
11	Etiology of myasthenia gravis: Innate immunity signature in pathological thymus. <i>Autoimmunity Reviews</i> , 2013, 12, 863-874.	2.5	75
12	Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 237-244.	1.1	73
13	Skeletal Muscle Laminopathies: A Review of Clinical and Molecular Features. <i>Cells</i> , 2016, 5, 33.	1.8	69
14	Autoimmune mechanisms in myasthenia gravis. <i>Current Opinion in Neurology</i> , 2012, 25, 621-629.	1.8	62
15	Innate immunity in myasthenia gravis thymus: Pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. <i>Journal of Autoimmunity</i> , 2014, 52, 74-89.	3.0	62
16	Increased Toll-Like Receptor 4 Expression in Thymus of Myasthenic Patients with Thymitis and Thymic Involution. <i>American Journal of Pathology</i> , 2005, 167, 129-139.	1.9	58
17	Myasthenia gravis: from autoantibodies to therapy. <i>Current Opinion in Neurology</i> , 2018, 31, 517-525.	1.8	58
18	Transforming Growth Factor- $\beta$ 1 in Polymyositis and Dermatomyositis Correlates with Fibrosis but not with Mononuclear Cell Infiltrate. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 479-484.	0.9	57

#	ARTICLE	IF	CITATIONS
19	<i>LMNA</i> -associated myopathies. <i>Neurology</i> , 2014, 83, 1634-1644.	1.5	57
20	The thymus in myasthenia gravis: Site of innate autoimmunity. <i>Muscle and Nerve</i> , 2011, 44, 467-484.	1.0	56
21	Exosomes and exosomal miRNAs from muscle-derived fibroblasts promote skeletal muscle fibrosis. <i>Matrix Biology</i> , 2018, 74, 77-100.	1.5	56
22	Allrecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF- $\beta$ in modulating proliferation. <i>International Immunology</i> , 2007, 19, 1063-1074.	1.8	53
23	Osteopontin is highly expressed in severely dystrophic muscle and seems to play a role in muscle regeneration and fibrosis. <i>Histopathology</i> , 2011, 59, 1215-1228.	1.6	53
24	Complete stable remission and autoantibody specificity in myasthenia gravis. <i>Neurology</i> , 2013, 80, 188-195.	1.5	53
25	Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. <i>Neuromuscular Disorders</i> , 2002, 12, 828-835.	0.3	51
26	Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. <i>International Immunology</i> , 2004, 16, 559-565.	1.8	51
27	Up-regulation of neural and cell cycle-related microRNAs in brain of amyotrophic lateral sclerosis mice at late disease stage. <i>Molecular Brain</i> , 2015, 8, 5.	1.3	49
28	Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection. <i>Immunobiology</i> , 2016, 221, 516-527.	0.8	47
29	Autophagy, Inflammation and Innate Immunity in Inflammatory Myopathies. <i>PLoS ONE</i> , 2014, 9, e111490.	1.1	44
30	A large cohort of myotonia congenita probands: novel mutations and a high-frequency mutation region in exons 4 and 5 of the <i>CLCN1</i> gene. <i>Journal of Human Genetics</i> , 2013, 58, 581-587.	1.1	42
31	Novel phenotype associated with a mutation in the <i>KCNA1</i> (Kv1.1) gene. <i>Frontiers in Physiology</i> , 2014, 5, 525.	1.3	42
32	Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype. <i>Journal of the Neurological Sciences</i> , 1995, 132, 146-155.	0.3	33
33	A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. <i>Immunobiology</i> , 2016, 221, 1227-1236.	0.8	33
34	Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells. <i>Experimental Neurology</i> , 2014, 253, 91-101.	2.0	31
35	Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. <i>Biomedicines</i> , 2020, 8, 21.	1.4	30
36	Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse. <i>Cell and Tissue Research</i> , 2014, 356, 427-443.	1.5	29

#	ARTICLE	IF	CITATIONS
37	Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 11-24.	1.8	28
38	<scp>VAV</scp>1 and <scp>BAFF</scp>, via <scp>NF</scp>ÎB pathway, are genetic risk factors for myasthenia gravis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 329-339.	1.7	27
39	FM19G11-Loaded Gold Nanoparticles Enhance the Proliferation and Self-Renewal of Ependymal Stem Progenitor Cells Derived from ALS Mice. <i>Cells</i> , 2019, 8, 279.	1.8	26
40	miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids. <i>Frontiers in Immunology</i> , 2020, 11, 142.	2.2	26
41	Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis. <i>Autoimmune Diseases</i> , 2011, 2011, 1-17.	2.7	25
42	Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. <i>Oncotarget</i> , 2015, 6, 7424-7437.	0.8	25
43	Elevated TGF Î2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. <i>Nucleus</i> , 2018, 9, 337-349.	0.6	25
44	Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate. <i>Pharmacological Research</i> , 2019, 141, 224-235.	3.1	25
45	Major histocompatibility complex class II molecule expression on muscle cells is regulated by differentiation: implications for the immunopathogenesis of muscle autoimmune diseases. <i>Journal of Neuroimmunology</i> , 1996, 68, 53-60.	1.1	24
46	Multidisciplinary study of a new CICâ€1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies. <i>FASEB Journal</i> , 2016, 30, 3285-3295.	0.2	24
47	Italian recommendations for diagnosis and management of congenital myasthenic syndromes. <i>Neurological Sciences</i> , 2019, 40, 457-468.	0.9	24
48	Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?. <i>Oncotarget</i> , 2017, 8, 95432-95449.	0.8	23
49	The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy. <i>Journal of Neuroimmunology</i> , 1998, 85, 52-58.	1.1	22
50	A New Thiopurine Sâ€Methyltransferase Haplotype Associated With Intolerance to Azathioprine. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 67-74.	1.0	21
51	The Kinesin Superfamily Motor Protein KIF4 Is Associated With Immune Cell Activation in Idiopathic Inflammatory Myopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 624-632.	0.9	20
52	A longitudinal DTI and histological study of the spinal cord reveals early pathological alterations in G93A-SOD1 mouse model of amyotrophic lateral sclerosis. <i>Experimental Neurology</i> , 2017, 293, 43-52.	2.0	19
53	Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia. <i>Neurogenetics</i> , 2017, 18, 219-225.	0.7	19
54	Agingâ€associated genes and <i>letâ€7</i> microRNAs: a contribution to myogenic program dysregulation in oculopharyngeal muscular dystrophy. <i>FASEB Journal</i> , 2019, 33, 7155-7167.	0.2	19

#	ARTICLE	IF	CITATIONS
55	Human adult skeletal muscle stem cells differentiate into cardiomyocyte phenotype in vitro. <i>Experimental Cell Research</i> , 2008, 314, 366-376.	1.2	17
56	New phenotype and neonatal onset of sodium channel myotonia in a child with a novel mutation of SCN4A gene. <i>Brain and Development</i> , 2015, 37, 891-893.	0.6	17
57	MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine. <i>Pharmacological Research</i> , 2019, 148, 104388.	3.1	16
58	T-Cell Infiltration in Polymyositis Is Characterized by Coexpression of Cytotoxic and T-Cell-Activating Cytokine Transcripts. <i>Annals of the New York Academy of Sciences</i> , 1995, 756, 418-420.	1.8	15
59	BDNF and its receptors in human myasthenic thymus: Implications for cell fate in thymic pathology. <i>Journal of Neuroimmunology</i> , 2008, 197, 128-139.	1.1	14
60	Hyperexcitability in Cultured Cortical Neuron Networks from the G93A-SOD1 Amyotrophic Lateral Sclerosis Model Mouse and its Molecular Correlates. <i>Neuroscience</i> , 2019, 416, 88-99.	1.1	14
61	Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5673.	1.8	14
62	Up-regulation of Toll-like receptors 7 and 9 and its potential implications in the pathogenic mechanisms of LMNA-related myopathies. <i>Nucleus</i> , 2018, 9, 398-409.	0.6	13
63	Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients. <i>Neuromuscular Disorders</i> , 2021, 31, 336-347.	0.3	13
64	Identification of previously unreported mutations in CHRNA1, CHRNE and RAPSN genes in three unrelated Italian patients with congenital myasthenic syndromes. <i>Journal of Neurology</i> , 2010, 257, 1119-1123.	1.8	11
65	Expression of Transforming Growth Factor- $\beta$ 1 in Thymus of Myasthenia Gravis Patients. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 278-283.	1.8	9
66	Epstein-Barr virus in myasthenia gravis thymus: A matter of debate. <i>Annals of Neurology</i> , 2011, 70, 519-519.	2.8	9
67	Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. <i>Clinical Immunology</i> , 2016, 173, 133-146.	1.4	9
68	VAPB depletion alters neurogenesis and phosphoinositide balance in motoneuron-like cells: relevance to VAPB-linked ALS. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	9
69	Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction. <i>Cells</i> , 2020, 9, 1532.	1.8	8
70	The empowerment of translational research: lessons from laminopathies. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 37.	1.2	7
71	Transcriptional and epigenetic analyses of the DMD locus reveal novel cis-acting DNA elements that govern muscle dystrophin expression. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017, 1860, 1138-1147.	0.9	7
72	Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment. <i>Brain Sciences</i> , 2019, 9, 299.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Clinical and Molecular Spectrum of Myotonia and Periodic Paralysis Associated With Mutations in SCN4A in a Large Cohort of Italian Patients. <i>Frontiers in Neurology</i> , 2020, 11, 646.	1.1	7
74	A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 51-56.	0.7	5
75	Comparison of Diffusion MRI Acquisition Protocols for the In Vivo Characterization of the Mouse Spinal Cord: Variability Analysis and Application to an Amyotrophic Lateral Sclerosis Model. <i>PLoS ONE</i> , 2016, 11, e0161646.	1.1	5
76	Biobank of Cells, Tissues and DNA from Patients with Neuromuscular Diseases: An Indispensable link between Clinical Centers and the Scientific Community. <i>Open Journal of Bioresources</i> , 2017, 4, .	1.5	4
77	Congenital myasthenic syndrome: phenotypic variability in patients harbouring p.T159P mutation in gene. <i>Acta Myologica</i> , 2017, 36, 28-32.	1.5	4
78	Rasmussen's encephalitis: update on pathogenesis and treatment. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 835-843.	1.4	3
79	Analysis of SjTREC Levels in Thymus from MG Patients and Normal Children. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 270-274.	1.8	2
80	Autoimmune Frontotemporal Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 259-262.	0.6	2
81	Pharmacogenetic and pharmacomiR biomarkers for tailoring and monitoring myasthenia gravis treatments. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 317-329.	0.4	2
82	T-Cell Receptor-CDR3 Sequences of Polymyositis Muscle-Infiltrating T-Lymphocytes Indicate a Conventional Antigen as Target. <i>Annals of the New York Academy of Sciences</i> , 1995, 756, 414-417.	1.8	1
83	Idiopathic Inflammatory Myopathies: A Review of Immunopathological Features and Current Models of Pathogenesis. , 0, , .		1
84	Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy. <i>Biomedicines</i> , 2022, 10, 1360.	1.4	1
85	Central core disease and susceptibility to malignant hyperthermia in a single family. <i>Journal of Neurology</i> , 2009, 256, 1161-1163.	1.8	0
86	Teaching Video Neuro Images : Clinical course of infantile ascending hereditary spastic paralysis. <i>Neurology</i> , 2014, 82, e61.	1.5	0
87	Epstein-Barr Virus in Myasthenia Gravis: Key Contributing Factor Linking Innate Immunity with B-Cell-Mediated Autoimmunity. , 0, , .		0
88	Inflammatory Myopathies. , 2006, , 119-134.		0